On May 22, 2025 Servier reported that it will present updates from its research programs at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting on May 30 – June 3 in Chicago (Press release, , MAY 22, 2025, View Source [SID1234653333]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentations will span across a range of cancers including chondrosarcoma, cholangiocarcinoma and myelodysplastic syndrome, reinforcing Servier’s commitment to the development of precision medicines for isocitrate dehydrogenase (IDH) mutated cancers.

"As industry leaders in IDH-mutated cancers, we look forward to sharing updates regarding the expansion of our clinical development program at this year’s ASCO (Free ASCO Whitepaper)," said Becky Martin, PhD, Chief of Medical at Servier Pharmaceuticals. "Innovation in precision medicine, including targeted therapies, is critical to improving outcomes for people living with cancer, and we are pleased to share updates on several Phase 3 programs that have the potential to bring new options to patients living with IDH-mutated cancers."

A full list of company-sponsored abstracts to be presented at ASCO (Free ASCO Whitepaper) can be found here.

In addition to its presence at ASCO (Free ASCO Whitepaper), Servier will also present research updates at the 30th European Hematology Association (EHA) (Free EHA Whitepaper) Congress on June 12-15 in Milan.